[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587931":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":40,"locations":47,"responsibleParty":65,"collaborators":68,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":45,"enrollmentInfo":84,"targetDuration":45,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":50,"whyStopped":45,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Sao Paulo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vasopressin","EXPERIMENTAL","Participants randomized to this arm will receive vasopressin intravenously in a blinded solution prepared by the pharmacy (final concentration: 0.12 U\u002FmL in 250 mL of 5% glucose solution). The infusion will start at 5 mL\u002Fh and will be titrated by 2.5 mL\u002Fh every 10 minutes up to a maximum of 30 mL\u002Fh, corresponding to doses between 0.01 and 0.06 U\u002Fmin. The infusion will be maintained until the target mean arterial pressure (MAP) ≥65 mmHg is achieved. If this target is not reached, open-label norepinephrine may be initiated. Hemodynamic and laboratory parameters will be collected at the start (T0) and after achieving target pressure (T1).",[13],"Drug: Vasopressin intravenous infusion",{"label":15,"type":16,"description":17,"interventionNames":18},"Noradrenaline","ACTIVE_COMPARATOR","Participants randomized to this arm will receive norepinephrine intravenously in a blinded solution prepared by the pharmacy (final concentration: 120 µg\u002FmL in 250 mL of 5% glucose solution). The infusion will start at 5 mL\u002Fh and will be titrated by 2.5 mL\u002Fh every 10 minutes up to a maximum of 30 mL\u002Fh, corresponding to doses between 10 and 60 µg\u002Fmin. The infusion will be maintained until the target mean arterial pressure (MAP) ≥65 mmHg is achieved. If this target is not reached, additional open-label norepinephrine may be started. Hemodynamic and laboratory parameters will be collected at the start (T0) and after achieving target pressure (T1).",[19],"Drug: Norepinephrine intravenous infusion",[21,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Vasopressin intravenous infusion","Vasopressin will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 0.12 U\u002FmL. The infusion will begin at 5 mL\u002Fh and be increased by 2.5 mL\u002Fh every 10 minutes during the first hour, up to a maximum rate of 30 mL\u002Fh (equivalent to doses from 0.01 to 0.06 U\u002Fmin). The target is to reach and maintain mean arterial pressure (MAP) ≥65 mmHg. If this is not achieved, open-label norepinephrine may be added. Hemodynamic and echocardiographic parameters will be measured before and after the target MAP is reached.",[9],[27,28,29],"Arginine Vasopressin","ADH","Pitressin",{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Norepinephrine intravenous infusion","Norepinephrine will be administered intravenously in a blinded 250 mL bag of 5% glucose solution, at a final concentration of 120 µg\u002FmL. The infusion will begin at 5 mL\u002Fh and be increased by 2.5 mL\u002Fh every 10 minutes during the first hour, up to a maximum rate of 30 mL\u002Fh (equivalent to doses from 10 to 60 µg\u002Fmin). The goal is to reach and maintain MAP ≥65 mmHg. If the MAP target is not reached, open-label norepinephrine may be initiated. Clinical and hemodynamic parameters will be collected at baseline and after MAP stabilization.",[15],[15,35],"Levophed",[37],{"name":38,"affiliation":5,"role":39},"Ludhmila A Hajjar, Full Professor","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"José León","CONTACT","+55 (11) 2661-5795",null,"aro@incor.usp.br",[48],{"facility":49,"status":50,"city":51,"state":45,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Instituto do Coração HCFMUSP","RECRUITING","São Paulo","05403-000","Brazil","BR",{"type":56,"coordinates":57},"Point",[58,59],-46.63611,-23.5475,{"lat":59,"lon":58},[62,64],{"name":63,"role":43,"phone":44,"phoneExt":45,"email":46},"José D León, Dr",{"name":38,"role":39,"phone":45,"phoneExt":45,"email":45},{"type":39,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"Ludhmila Abrahão Hajjar MD, PhD","Full Professor",[69,72],{"name":70,"class":71},"Hospital Universitário Cassiano Antônio de Moraes\u002FHUCAM","UNKNOWN",{"name":73,"class":71},"Hospital Santa Casa de Misericórdia de Vitória","100587931","phase-4-inotropic-effects-of-vasopressin-versus-noradrenaline-in-patients-with-vasoplegic-syndrome-after-cardiac-surgery-100587931",false,"NCT06934798","Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery","INVASC","Inclusion Criteria:\n\n* Age over 18.\n* Patients undergoing coronary artery bypass grafting, valve surgery or both, with a diagnosis of vasoplegic syndrome in the immediate postoperative period (\\\u003C24 hours), defined as mean arterial pressure \\\u003C 65 mmHg (measured using an invasive blood pressure catheter) and resistance to fluid replacement - at least 1000ml of crystalloids.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Aortic surgery.\n* Surgeries to correct congenital heart disease.\n* Heart transplants.\n* Emergency surgery.\n* Use of vasopressor therapy in the preoperative period.\n* Presence of a ventricular assist device other than an intra-aortic balloon in the postoperative period.\n* Severe hyponatremia in the postoperative period (serum sodium less than 130mEq\u002Fl).\n* Postoperative acute coronary syndrome.\n* Mesenteric ischemia in the postoperative period.\n* History of Raynaud's disease.\n* History of neoplasia.",true,"ALL","18 Years",{"count":85,"type":86},350,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","This is a randomized, double-blind clinical trial designed to compare the inotropic effects of vasopressin versus norepinephrine in patients who develop vasoplegic syndrome in the immediate postoperative period following cardiac surgery.\n\nVasoplegic syndrome is characterized by severe hypotension due to systemic vasodilation, despite adequate fluid resuscitation and preserved or elevated cardiac output. Vasopressors are essential in restoring hemodynamic stability in this context; however, their impact on myocardial performance remains uncertain. While norepinephrine is the standard first-line agent, vasopressin has shown potential benefits, including reduced catecholamine exposure and fewer adverse cardiovascular effects.\n\nThis study aims to assess changes in cardiac output and other echocardiographic and hemodynamic parameters after administration of either vasopressin or norepinephrine. The findings are expected to contribute to optimizing vasopressor selection in vasoplegic patients after cardiac surgery and improving clinical outcomes.",[92],"Vasoplegic Syndrome of Cardiac Surgery",[94,95,96],"Shock Cardiogenic","Postoperative Complications","Cardiac Surgical Procedures","2025-04-25",{"date":99,"type":100},"2025-04-30","ACTUAL",{"date":102,"type":100},"2024-04-01",{"date":104,"type":86},"2025-07-30",{"name":5,"class":6},1]